ArticleVaccine2022

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.

Jerald Sadoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.